Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31

Katherine L. Pogue-Geile, Chungyeul Kim, Jong Hyeon Jeong, Noriko Tanaka, Hanna Bandos, Patrick G. Gavin, Debora Fumagalli, Lynn C. Goldstein, Nour Sneige, Eike Burandt, Yusuke Taniyama, Olga L. Bohn, Ahwon Lee, Seung Il Kim, Megan L. Reilly, Matthew Y. Remillard, Nicole L. Blackmon, Seong Rim Kim, Zachary D. Horne, Priya RastogiLouis Fehrenbacher, Edward H. Romond, Sandra M. Swain, Eleftherios P. Mamounas, D. Lawrence Wickerham, Charles E. Geyer, Joseph P. Costantino, Norman Wolmark, Soonmyung Paik

Research output: Contribution to journalArticlepeer-review

91 Citations (Scopus)


Background National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31 suggested the efficacy of adjuvant trastuzumab, even in HER2-negative breast cancer. This finding prompted us to develop a predictive model for degree of benefit from trastuzumab using archived tumor blocks from B-31. Methods Case subjects with tumor blocks were randomly divided into discovery (n = 588) and confirmation cohorts (n = 991). A predictive model was built from the discovery cohort through gene expression profiling of 462 genes with nCounter assay. A predefined cut point for the predictive model was tested in the confirmation cohort. Gene- by-treatment interaction was tested with Cox models, and correlations between variables were assessed with Spearman correlation. Principal component analysis was performed on the final set of selected genes. All statistical tests were two-sided. Results Eight predictive genes associated with HER2 (ERBB2, c17orf37, GRB7) or ER (ESR1, NAT1, GATA3, CA12, IGF1R) were selected for model building. Three-dimensional subset treatment effect pattern plot using two principal components of these genes was used to identify a subset with no benefit from trastuzumab, characterized by intermediate-level ERBB2 and high-level ESR1 mRNA expression. In the confirmation set, the predefined cut points for this model classified patients into three subsets with differential benefit from trastuzumab with hazard ratios of 1.58 (95% confidence interval [CI] = 0.67 to 3.69; P = .29; n = 100), 0.60 (95% CI = 0.41 to 0.89; P = .01; n = 449), and 0.28 (95% CI = 0.20 to 0.41; P < .001; n = 442; Pinteraction between the model and trastuzumab < .001). Conclusions We developed a gene expression-based predictive model for degree of benefit from trastuzumab and demonstrated that HER2-negative tumors belong to the moderate benefit group, thus providing justification for testing trastuzumab in HER2-negative patients (NSABP B-47).

Original languageEnglish
Pages (from-to)1782-1788
Number of pages7
JournalJournal of the National Cancer Institute
Issue number23
Publication statusPublished - 2013 Dec 4


Dive into the research topics of 'Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31'. Together they form a unique fingerprint.

Cite this